Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
san francisco blog main
san francisco top stories
15
×
boston top stories
national top stories
biotech
clinical trials
new york blog main
new york top stories
deals
boston
cancer
startups
eli lilly
fda
indiana blog main
indiana top stories
ipo
sanofi
novartis
san diego blog main
san diego top stories
vc
wisconsin blog main
wisconsin top stories
amgen
boulder/denver blog main
boulder/denver top stories
cancer drugs
detroit blog main
detroit top stories
europe blog main
europe top stories
genentech
national
non-small cell lung cancer
raleigh-durham blog main
raleigh-durham top stories
What
medicines
15
×
cancer
new
drug
bio
deal
fda
ipo
research
approval
announced
big
biotech
blueprint
ceo
companies
covid
developing
diseases
drugs
gets
latest
pharmaceutical
proteins
ret
revolution
rna
roundup
startup
targeted
way
years
abandoning
aces
acquisitions
activity
address
ago
aim
aiming
Language
unset
Current search:
medicines
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines